Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression

Journal of Cellular Physiology

Volumn 180, Issue 2, 1999, Pages 225-235

  Wilhelm, Olaf G ^a   Wilhelm, Sabine ^a   Escott, Gemma M ^b   Lutz, Verena ^a   Magdolen, Viktor ^a   Schmitt, Manfred ^a   Rifkin, Daniel B ^c   Wilson, E Lynette ^c   Graeff, Henner ^a   Brunner, Georg ^b,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Kaplan Cancer Center   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHOLIPASE D; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; DISEASE MARKER; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TUMOR GROWTH;

ANTISENSE ELEMENTS (GENETICS); FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; HYDROLYSIS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PHOSPHOLIPASE D; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033059340     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199908)180:2<225::AID-JCP10>3.0.CO;2-2     Document Type: Article

References (60)

1. Abe M, Harpel JG, Metz CN, Nunes DJ, Loskutoff DJ, Rifkin DB. 1994. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter luciferase construct. Anal Biochem 216:276-284.
2. Almqvist P, Carlsson SR. 1988. Characterization of a hydrophilic form of Thy-1 purified from human cerebrospinal fluid. J Biol Chem 263:12709-12715.
3. Black PH. 1980. Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32:75-199.
4. Bordier C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 256:1604-1607.
5. Brunner G, Preissner T. 1994. Pericellular enzymatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinolysis 5:625-639.
6. Brunner G, Metz CN, Nguyen H, Gabrilove J, Patel SR, Davitz MA, Rifkin DB, Wilson EL. 1994. An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures. Blood 83:2115-2125.
7. Casslen B, Nordengren J, Gustavsson B, Nilbert M, Lund LR. 1995. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J Clin Endocrinol Metab 80:2776-2784.
8. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. 1998. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91:2305-2312.
9. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-162.
10. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F. 1995. Alpha-2 macroglobulin receptor/LDL receptor-related protein(LRP)-dependent internalization of the urokinase receptor. J Cell Biol 131:1609-1622.
11. Dang J, Wang Y, Doe WF. 1995. Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells. FEBS Lett 359:147-150.
12. Danø K, Andreasen PA, Grøhndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. 1985. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
13. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. 1994. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189-203.
14. Davitz MA, Horn J, Schenkman S. 1989. Purification of a glycosylphosphatidylinositol-specific phospholipase D from human plasma. J Biol Chem 264:13760-13764.
15. Deeg MA, Verchere CB. 1997. Regulation of glycosylphosphatidylinositol-specific phospholipase D secretion from βTC3 cells. Endocrinology 138:819-826.
16. de Witte H, Sweep F, Brünner N, Heuvel J, Beex L, Grebenschikov N, Benraad T. 1998. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 77:236-242.
17. Dumler I, Petri T, Schleuning WD. 1993. Interaction of urokinase-type plasminogen activator (uPA) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 322:37-40.
18. Flaumenhaft R, Rifkin DB. 1992. The extracellular regulation of growth factor action. Mol Biol Cell 3:1057-1065.
19. Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG. 1994. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93:1380-1387.
20. Gyetko MR, Sitrin RG, Fuller FA, Todd RF 3rd, Petty H, Standiford TJ. 1995. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leukoc Biol 58:533-538.
21. Hedberg KK, Danø K, Rønne E, Griffith OH. 1997. The receptor for urokinase type plasminogen activator is deposited on the substratum by both normal and tumor-derived human cells in culture: studies by fluorescence and photoelectron microscopy. Fibrinol Proteol 11:A44.
22. Kanse S, Kost C, Wilhelm O, Andreasen P, Preissner K. 1996. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224:344-353.
23. Klausner RD, Donaldson JG, Lippincott-Schwartz J. 1992. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 116:1071-1080.
24. Lierheimer R, Kunz B, Vogt L, Savoca R, Brodbeck U, Sonderegger P. 1997. The neuronal cell-adhesion molecule axonin-1 is specifically released by an endogenous glycosylphosphatidylinositol-specific phospholipase. Eur J Biochem 243:502-510.
25. Low MG, Huang K-S. 1991. Factors affecting the ability of glycosylphosphatidylinositol-specific phospholipase D to degrade the membrane anchors of cell surface proteins. Biochem J 279:483-493.
26. Lund LR, Ellis V, Rønne E, Pyke C, Danø K. 1995. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinom cell line A549. Biochem J 310:345-352.
27. Meissauer A, Kramer MD, Schirrmacher V, Brunner G. 1992. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res 199:179-190.
28. Metz CN, Brunner G, Choi-Muira NH, Nguyen H, Gabrilove J, Caras IW, Altszuler N, Rifkin DB, Wilson EL, Davitz MA. 1994. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 13:1741-1751.
29. Mizukami IF, Todd RF 3rd. 1998. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol 64:203-213.
30. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF. 1995. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86:203-211.
31. Möbus V, Gerharz CD, Press U, Beck T, Mellin W, Pollow K, Knapstein PG, Kreienberg R. 1992. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52:76-84.
32. Moolenaar WH, Kranenburg O, Postma FR, Zondag GCM. 1997. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 9:168-173.
33. Mustjoki R, Alitalo R, Stephens RW, Tapiovaara H, Siren V, Vaheri A. 1997. Plasminogen activation in human leukemia. Fibrinol Proteol 11:A95.
34. Nakano Y, Noda K, Endo T, Kobata A, Tomita M. 1994. Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. Arch Biochem Biophys 311:117-126.
35. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. 1992. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11:4825-4833.
36. Narayama R, Lawlor KG, Schaapveld R, Cho K, Vogelstein B, Tran PB, Osborne MP, Telang NT. 1992. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7:553-559.
37. Noda-Heiny H, Daugherty A, Sobel BE. 1995. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vase Biol 15:37-43.
38. Odekon LE, Sato Y, Rifkin DB. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 150:258-263.
39. Ossowski L. 1988. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107:2437-2445.
40. Pappot H, Høyer-Hansen G, Rønne E, Hansen HH, Brünner N, Danø K, Grøndahl-Hansen J. 1997. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 33:867-872.
41. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Danø K, Kuhn W, Jänicke F, Blasi F. 1993. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160-2167.
42. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. 1991. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926-1933.
43. Rabbani SA, Mazar AP, Bernier S, Haq M, Bolivar I, Henkin J, Goltzman D. 1992. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 276:14151-14156.
44. Rao NK, Shi GP, Chapman HA. 1995. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 96:465-474.
45. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572-1582.
46. Rolfs A, Schuller I, Finck U, Weber-Rolfs I. 1992. PCR: clinical diagnostics and research. Berlin: Springer. p 99-111.
47. Shetty S, Kumar A, Idell S. 1997. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 17:1075-1083.
48. Sier K, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. 1998. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843-1849.
49. Sitrin RG, Todd RF 3rd, Mizukami IF, Gross TJ, Shollenberger SB, Gyetko MR. 1994. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 84:1268-1275.
50. Sitrin RG, Todd RF 3rd, Albrecht E, Gyetko MR. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 97:1942-1951.
51. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N. 1997. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876.
52. Tsang TC, Fung W-J, Levine J, Metz CN, Davitz MA, Burns DK, Huang KS, Kochan JP. 1992. Isolation and expression of two human glycosylphosphatidylinositol phospholipase D (GPI-PLD) cDNAs. FASEB J 6:A1922.
53. Wahlberg K, Høyer-Hansen G, Casslen B. 1998. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 58:3294-3298.
54. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388.
55. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. 1996. Regulation of integrin function by the urokinase receptor. Science 273:1551-1555.
56. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H. 1994. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). FEBS Lett 337:131-134.
57. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R, Graeff H. 1995. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13:296-302.
58. Will C, Wilhelm O, Höhl S, Möbus V, Weidle U, Kreienberg R, Jänicke F, Schmitt M, Graeff H. 1994. Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human ovarian cancer cells and in vitro invasion capacity. Int J Oncol 5:753-761.
59. Xie M, Low MG. 1994. Expression and secretion of glycosylphosphatidylinositol-specific phospholipase D by myeloid cell lines. Biochem J 297:547-554.
60. Xie M, Sesko AM, Low MG. 1993. Glycosylphosphatidylinositol-specific phospholipase D is localized in keratinocytes. Am J Physiol 265:C1156-C1168.